EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: A Multicenter Retrospective Study

Dharmesh Gopalakrishnan, Yu Fujiwara, Katharine A. Collier, Joseph J. Park, Jacob P. Zaemes, Elaine T. Lam, Sabah Alaklabi, Ellen B. Jaeger, Pedro C. Barata, Eric C. Kauffman, Michael B. Atkins, Ajjai Alva, Yuanquan Yang, Saby George

Journal of the National Comprehensive Cancer Network · 2026-11 · 24 (11)

DOI: 10.6004/jnccn.2026.7058 ↗
AbstractBibliografische Angaben

Abstract

Background: Metastatic sarcomatoid renal cell carcinoma (msRCC) is an aggressive disease typically associated with poor outcomes following VEGF-targeted therapies. This study evaluated in real-world outcomes in patients with msRCC based on whether they received treatment with immune checkpoint inhibitors (ICIs). Methods: We conducted a multi-institutional, retrospective study of patients who received systemic therapy for msRCC between July 2010 and June 2020. In total, 203 patients across 6 US academic centers were included. Patients were categorized into 2 groups based on whether they received ICIs: ICI+ (n=155) and ICI− (n=48). Overall survival (OS) was estimated using the Kaplan–Meier method and measured from the initiation of frontline systemic therapy. Treatment responses were evaluated by investigators at participating centers. Results: After a median follow-up of 48.1 months, OS was significantly longer in the ICI+ group (median OS, 31.0 vs 7.6 months; hazard ratio [HR], 0.38; 95% CI, 0.26–0.56; P

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →